Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
182
resultados
Última actualización
26/07/2026 [07:34:00]
Resumen de: AU2025215148A1
The present disclosure provides for treating Parkinson´s disease (PD) comprising administering acetyl-leucine or a pharmaceutically acceptable salt thereof to a subject in need thereof.
Resumen de: AU2026205314A1
Abstract Dosage regimens for SOD1-targeting antisense oligonucleotides, and salts thereof, are provided. These dosage regimens find use in the treatment of subjects having or at risk of developing amyotrophic lateral sclerosis. Abstract ul b s t r a c t u l
Resumen de: US20260209350A1
0000 The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.
Resumen de: US20260209695A1
0000 Disclosed are novel strategies for the treatment of patients with Parkinson's disease and other secondary Parkinsonian disorders. Disclosed are DA neuronal cells that have been modified in vitro with a genetic insertion of GDNF. The GDNF coding sequence is inserted under the transcriptional control of a promotor such that secreted proteins are made and taken up by the endogenous cells after the administered engineered cells have matured to a Neuronal Mature Cell Type to promote survival of endogenous neurons. Also disclosed are DA neuronal cells that have been modified with a genetic insertion of GBA in vitro and are hemizygous null for SNCA. The GBA coding sequence is inserted under the transcriptional control of a ubiquitous promotor and the secreted proteins are made and taken up by the graft and endogenous cells immediately upon transplantation to promote long-term graft integrity.
Resumen de: US20260207575A1
Provided herein a method of treating Juvenile Huntington disease in a subject in need thereof comprising orally administering a pharmaceutical composition comprising pridopidine and/or its analog or a pharmaceutically acceptable salt thereof.
Resumen de: US20260209771A1
The present disclosure relates to an antisense oligonucleotide suitable for editing an adenosine in a target RNA nucleic acid sequence to inosine (A-to-I editing), wherein the antisense oligonucleotide comprises a sequence that is substantially complementary to the target RNA nucleic acid sequence: 5′-A C U A C A G C A U U G C-3′ (SEQ ID NO: 1), or complementary to a sequence that has at least 80% sequence identity to SEQ ID NO: 1, wherein A is the target adenosine to be edited in the target nucleic acid; and the antisense oligonucleotide can be represented by: 3′-X−5 X−4 X−3 X−2 X−1 X0 X+1 X+2 X+3 X+4 X+5 X+6 X+7-5′, wherein X represents a nucleic acid, X0 represents cytosine (C), deoxycytosine (dC), or uracil (U) directly opposite to the target adenosine to be edited, and wherein there is a mismatch between the antisense oligonucleotide and the target nucleic acid at one or more of the following position(s): a) −5 (X−5); b)+3 (X+3); c)+7 (X+7); d)+7 (X+7) and +2 (X+2); e)+7 (X+7) and −5 (X−5); or f)+6 (X+6) and −5 (X−5).
Resumen de: US20260207625A1
0000 The present invention is directed to the compound golexanolone for use in the treatment of Parkinson's Disease (PD) or for use in the treatment of L-dopa Induced Dyskinesia (LID) in Parkinson's Disease (PD) patients. Further, the present invention is directed to the compound golexanolone or a pharmaceutically acceptable salt thereof, for use in the treatment of Parkinson's Diseases (PD) patients, in particular PD patients exhibiting a L-dopa Induced Dyskinesia (LID).
Resumen de: US20260207794A1
The present invention relates to novel compounds of formula (I), or a detectably labelled compound, stereoisomer, racemic mixture, pharmaceutically acceptable salt, hydrate, or solvate thereof, that can be employed in the imaging of alpha-synuclein aggregates and determining an amount thereof. Furthermore, the compounds can be used for diagnosing a disease, disorder or abnormality associated with an alpha-synuclein aggregates (such as Parkinson's disease or such as multiple system atrophy (MSA)) determining a predisposition to such a disease, disorder or abnormality, prognosing such a disease, disorder or abnormality, monitoring the evolution of the disease in a patient suffering from such a disease, disorder or abnormality, monitoring the progression of such a disease, disorder or abnormality and predicting responsiveness of a patient suffering from such a disease, disorder or abnormality to a treatment thereof.
Resumen de: US20260209725A1
0000 Compounds, compositions, uses, and methods for increasing cell viability of a dopaminergic neuron, or for preventing or treating dopaminergic neuronal death, are provided herein. In certain examples, methods for reducing symptoms and/or for preventing or treating Parkinson's disease in a subject in need thereof are provided which may include a step of treatment with a GDP-bound form of Rab1a (Rab1a
Resumen de: AU2025231111A1
Provided herein are antibodies that target Galectin-3. Such antibodies are used in methods of treating epilepsy and related neurological disorders, such as Alzheimer's disease (AD) and Parkinson's disease (PD).
Resumen de: WO2025056518A1
The present invention relates to the field of medicinal chemistry and more specifically to 5,6- disubstituted 1H- and 2H- indazoles as pharmaceutically active compounds. The compounds of the present invention are dual inhibitors of butyrylcholinesterase and p38α mitogen-activated protein kinase, and thus are particularly useful for the treatment of various diseases which may be therapeutically modified by altering the activity of butyrylcholinesterase (BChE) and/or p38α MAP kinase such as dementias including Alzheimer's disease (AD) and other conditions involving chronic inflammation.
Resumen de: EP4778582A2
The present invention relates to antisense oligonucleotides that are complimentary to SOD1, leading to decreased expression of SOD1. Reduced expression of SOD1 is beneficial in medical disorders such as Amyotrophic Lateral Sclerosis.
Resumen de: EP4778518A2
0001 The present disclosure provides methods and compositions for treating fall-related symptoms in patients with neurodegenerative diseases such as Parkinson's disease or Parkinson-related diseases. In some embodiments, the disclosure utilizes nicotine or a salt thereof in combination of dopaminergic agent treatments for reducing fall-related symptoms such as reducing frequency of fall, reducing injuries related to fall, reducing severity of injuries related to fall, freezing of gait, improving posture stability, improving locomotion ability, improving balance and gait. In some embodiments, the methods predict fall frequency and tendency of recurrent falls in patients with Parkinson's disease, in particular, patients with typical Parkinson's disease.
Resumen de: AU2024400795A1
Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.
Resumen de: AU2024406047A1
The present disclosure is directed to compounds of Formula I and their use as TREM2 agonists for treatment and prevention of a neurodegenerative disorder associated with a loss of function of human TREM2. The disclosed TREM2 agonists may be useful for the treatment of Alzheimer's Disease and associated neurological conditions.
Resumen de: AU2024403764A1
The present disclosure is directed to compounds of Formula (I) and their use as TREM2 agonists for treatment and prevention of a neurodegenerative disorder associated with a loss of function of human TREM2. The disclosed TREM2 agonists may be useful for the treatment of Alzheimer's Disease and associated neurological conditions.
Resumen de: WO2026148695A1
The present invention relates to the technical field of medicines, and specifically relates to a deuterated huperzine A compound or a pharmaceutically acceptable salt thereof, and a preparation method therefor and a use thereof. The structure of the deuterated huperzine A compound is as follows, wherein R1-R9 are each independently H or D, and are not both H. The present invention has the advantages of high chemical stability, long metabolic half-life, low toxicity, significant synergistic effect with bremelanotide in the treatment of Alzheimer's disease, and ability to reduce the toxicity of bremelanotide.
Resumen de: AU2025210321A1
This invention provides a method of prolonging the survival of subjects afflicted with ALS by administering a composition comprising pridopidine or pharmaceutically acceptable salt thereof.
Resumen de: US20260199232A1
A polymer layer containing a pharmaceutical drug substance-loaded amino group and a nanomotor containing a metal layer for orientation by a magnetic field is used to treat Alzheimer's Disease; Memantine HCl-loaded nanomotors are synthesized with a biocompatible poly-L-lysine polymer whose movement is directly controlled by the magnetic field and targets the brain by crossing the blood brain barrier by providing movement in the magnetic field.
Resumen de: US20260199270A1
Provided herein are methods for treating Alzheimer's disease using a combination of tramiprosate, a tramiprosate prodrug or an active tramiprosate metabolite with at least one amyloid plaque clearing agent.
Resumen de: US20260199365A1
Provided are compounds and pharmaceutically acceptable salt, solvate and/or derivative thereof. Further, provided are methods of treating a disease, disorder or condition mediated or treatable by activation of SHIP1 comprising administering a SHIP1 activator compound or a pharmaceutically acceptable salt, solvate or derivative thereof. The compound or a pharmaceutically acceptable salt, solvate or derivative thereof may be used in the treatment of SHIP1 mediated disease, disorder or conditions including inflammatory bowel disease (IBD), Crohn′ disease, COPD, ulcerative colitis, arthritis, and Alzheimer's Disease.
Resumen de: US20260201025A1
The invention relates to combinational treatment using a monoclonal anti-alpha-synuclein antibody and an additional medicament. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy together with another medicament of the invention.
Resumen de: US20260200848A1
The present disclosure describes crystalline forms of 2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol fumarate salts and pharmaceutical compositions of same. Also described are methods of using the crystalline forms treating Alzheimer's Disease, Dementia with Lewy Bodies and Dry age-related macular degeneration in a subject in need thereof, comprising administering the crystalline form to the subject. Methods of making the solid forms are also described.
Resumen de: US20260199329A1
0000 The subject invention pertains to a composition comprising a series of compounds selectively targeting G-quadruplexes (G4s) formed by the GGGGCC (G4C2) hexanucleotide repeats (HREs) of C9orf72, (G4C2)
Nº publicación: US20260201390A1 16/07/2026
Solicitante:
NORTHWESTERN UNIV [US]
Northwestern University
Resumen de: US20260201390A1
The present disclosure provides compositions and methods for the treatment of levodopa-induced dyskinesia (LID) and Parkinson's disease (PD) therewith. In particular, the present disclosure provides methods for treating LID in PD by inhibiting (e.g., expression of) Muscarinic M1 acetylcholine receptor (M1Rs), for example, in indirect pathway spiny projection neurons (iSPNs) to attenuate LID without compromising of the treatment with levodopa (e.g., boosting the efficacy of levodopa treatment).
BOPI
Sede Electrónica
